VP22 and cytosine deaminase fusion gene modified tissue-engineered neural stem cells for glioma therapy.
about
VP22 core domain from Herpes simplex virus 1 reveals a surprising structural conservation in both the Alpha- and Gammaherpesvirinae subfamiliesExpression, purification and production of antisera against recombinant truncated VP22 proteinCombined treatment, based on lysomustine administration with mesenchymal stem cells expressing cytosine deaminase therapy, leads to pronounced murine Lewis lung carcinoma growth inhibition.Ferritin heavy chain as a molecular imaging reporter gene in glioma xenografts.
P2860
VP22 and cytosine deaminase fusion gene modified tissue-engineered neural stem cells for glioma therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
VP22 and cytosine deaminase fu ...... stem cells for glioma therapy.
@en
VP22 and cytosine deaminase fu ...... stem cells for glioma therapy.
@nl
type
label
VP22 and cytosine deaminase fu ...... stem cells for glioma therapy.
@en
VP22 and cytosine deaminase fu ...... stem cells for glioma therapy.
@nl
prefLabel
VP22 and cytosine deaminase fu ...... stem cells for glioma therapy.
@en
VP22 and cytosine deaminase fu ...... stem cells for glioma therapy.
@nl
P2093
P2860
P1476
VP22 and cytosine deaminase fu ...... stem cells for glioma therapy.
@en
P2093
Fusheng Liu
Guidong Zhu
Guishan Jin
Yiqiang Zhou
P2860
P2888
P304
P356
10.1007/S00432-012-1347-3
P577
2012-11-22T00:00:00Z